The RAS inhibitor salirasib has been shown to impact transcriptional response across five different cancer cell lines effecting E2F-regulated and NF-Y regulated genes and the transcription factor FOS which control cell proliferation, blocks apoptosis, and induction of activating transcription factor BACH2 regulated genes which participate in translation and stress response (Blum et al., 2007). This evidence concerns the gene FOS and cancer.